Accredited Investor? We Have a Deal Available Right Now! Click Here to Schedule a Call and Get Full Access

Life Sciences Venture Capital Monitor – Europe 02/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 02/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of February 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 977m 
  • Top 5 Deals exceed EUR 40m each, largest transaction amounted to EUR 130m in Amolyt Pharma (France)
  • Flerie Invest (Sweden) dominates the Top 5 Investors (by deal volume), followed by Novo Holdings (Denmark) and EQT Life Sciences (Netherlands)
  • Biotech received 56% of the total investment volume (+7 compare to the previous month)
  • Oncology dominates as the top indication in Biotechnology

To access the full report, please click here.

By Dr. Mathias Schott,  Johannes Link and Marco Buonafede-Bennardo.

Source link

Related Articles